modelRetigabine
Extends from Pharmacolibrary.Drugs.ATC.N.N03AX21.
Information
| name: | Retigabine | |
| ATC code: | N03AX21 | route: | oral |
| compartments: | 1 | |
| dosage: | 200 | mg |
| volume of distribution: | 7.5 | L |
| clearance: | 0.038 | L/h/kg |
| other parameters in model implementation | ||
Retigabine (also known as ezogabine) is an anticonvulsant medication used as adjunctive therapy in the treatment of partial-onset seizures in epilepsy. It acts primarily as a potassium channel opener (KCNQ potassium channel agonist). Retigabine was approved in the EU and US but has been discontinued due to safety concerns including retinal abnormalities and skin discoloration.
Pharmacokinetics
Pharmacokinetics reported for healthy adult volunteers after single oral dose.
References
Jacob, S, & Nair, AB (2016). An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs in R&D 16(4) 303–316. DOI:10.1007/s40268-016-0148-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27766590
Ferron, GM, et al., & Troy, S (2002). Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. Journal of clinical pharmacology 42(2) 175–182. DOI:10.1177/00912700222011210 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11831540
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)